BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes
- PMID: 8648868
BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes
Abstract
Objectives: To identify predictors of utilization of breast-ovarian cancer susceptibility (BRCA1 gene) testing and to evaluate outcomes of participation in a testing program.
Design: Prospective cohort study with baseline interview assessment of predictor variables (eg, sociodemographic factors, knowledge about hereditary cancer and genetic testing, perceptions of testing benefits, limitations, and risks). BRCA1 test results were offered after an education and counseling session in a research setting. Outcome variables (including depression, functional health status, and prophylactic surgery plans [follow-up only]) were assessed at baseline and 1-month follow-up interviews.
Participants: Adult male and female members (n=279) of families with BRCA1-linked hereditary breast-ovarian cancer (HBOC).
Results: Of subjects who completed a baseline interview (n=192), 60% requested BRCA1 test results (43% of all study subjects requested results). Requests for results were more frequent for persons with health insurance (odds ration [OR], 3.74; 95% confidence interval [CI], 2.06-6.80); more first-degree relatives affected with breast cancer (OR, 1.59; 95% CI, 1.16-2.16); more knowledge about BRCA1 testing (OR, 1.85; 95% CI, 1.36-2.50); and indicating that test benefits are important (OR, 1.45; 95% CI, 1.13-1.86). At follow-up, noncarriers of BRCA1 mutations showed statistically significant reductions in depressive symptoms and functional impairment compared with carriers and nontested individuals. Individuals identified as mutation carriers did not exhibit increases in depression and functional impairment. Among unaffected women with no prior prophylactic surgery, 17% of carriers (2/12) intended to have mastectomies and 33% (4/12) to have oophorectomies.
Conclusions: Only a subset of HBOC family members are likely to request BRCA1 testing when available. Rates of test use may be higher in persons of a higher socioeconomic status and those with more relatives affected with breast cancer. For some high-risk individuals who receive test results in a research setting that includes counseling, there may be psychological benefits. More research is needed to assess the generalizability of these results and evaluate the long-term consequences of BRCA1 testing.
Comment in
-
Testing for inherited cancer susceptibility.JAMA. 1996 Jun 26;275(24):1928-9. JAMA. 1996. PMID: 8648875 No abstract available.
-
Genetic testing of families with hereditary diseases.JAMA. 1996 Oct 9;276(14):1138-9; author reply 1140. JAMA. 1996. PMID: 8827962 No abstract available.
-
Genetic testing of families with hereditary diseases.JAMA. 1996 Oct 9;276(14):1139; author reply 1140. doi: 10.1001/jama.276.14.1139b. JAMA. 1996. PMID: 8827963 No abstract available.
-
Genetic testing of families with hereditary diseases.JAMA. 1996 Oct 9;276(14):1139-40; author reply 1140. doi: 10.1001/jama.1996.03540140027018. JAMA. 1996. PMID: 8827964 No abstract available.
Similar articles
-
What you don't know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing.J Clin Oncol. 1998 May;16(5):1650-4. doi: 10.1200/JCO.1998.16.5.1650. J Clin Oncol. 1998. PMID: 9586874
-
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.Gynecol Oncol. 2005 May;97(2):457-67. doi: 10.1016/j.ygyno.2005.01.039. Gynecol Oncol. 2005. PMID: 15863145
-
Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.JAMA. 1997 Mar 26;277(12):997-1003. JAMA. 1997. PMID: 9091675 Review.
-
Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing.Prev Med. 2000 Jul;31(1):75-80. doi: 10.1006/pmed.2000.0684. Prev Med. 2000. PMID: 10896846
-
Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87. doi: 10.1006/gyno.2000.5861. Gynecol Oncol. 2000. PMID: 10985881 Review.
Cited by
-
Patient Motivation, Satisfaction, and Coping in Genetic Counseling and Testing for BRCA1 and BRCA2.J Genet Couns. 2000 Jun;9(3):219-35. doi: 10.1023/A:1009463905057. J Genet Couns. 2000. PMID: 26141318
-
Bilingual approach to online cancer genetics education for Deaf American Sign Language users produces greater knowledge and confidence than English text only: A randomized study.Disabil Health J. 2017 Jan;10(1):23-32. doi: 10.1016/j.dhjo.2016.07.002. Epub 2016 Jul 28. Disabil Health J. 2017. PMID: 27594054 Free PMC article. Clinical Trial.
-
Emotional responses to APO E genotype disclosure for Alzheimer disease.J Genet Couns. 2005 Apr;14(2):141-50. doi: 10.1007/s10897-005-4063-1. J Genet Couns. 2005. PMID: 15959645
-
Retrospective comparison of patient outcomes after in-person and telephone results disclosure counseling for BRCA1/2 genetic testing.Fam Cancer. 2010 Jun;9(2):203-12. doi: 10.1007/s10689-009-9303-3. Fam Cancer. 2010. PMID: 20473602
-
Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.Fam Cancer. 2009;8(4):277-87. doi: 10.1007/s10689-009-9242-z. Epub 2009 Apr 4. Fam Cancer. 2009. PMID: 19347608
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous